Cigogne Management SA Takes $1.78 Million Position in Grifols, S.A. (NASDAQ:GRFS)

Cigogne Management SA acquired a new stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 238,928 shares of the biotechnology company's stock, valued at approximately $1,778,000. Grifols makes up about 1.1% of Cigogne Management SA's holdings, making the stock its 29th biggest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Syon Capital LLC acquired a new position in Grifols during the 4th quarter worth $197,000. Stifel Financial Corp increased its stake in Grifols by 5.5% in the fourth quarter. Stifel Financial Corp now owns 123,878 shares of the biotechnology company's stock valued at $922,000 after purchasing an additional 6,417 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares during the last quarter. Capital World Investors increased its stake in Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company's stock valued at $157,239,000 after purchasing an additional 154,358 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in Grifols in the fourth quarter valued at approximately $75,000.

Analyst Ratings Changes

Separately, Morgan Stanley started coverage on shares of Grifols in a research note on Wednesday, February 12th. They issued an "overweight" rating on the stock.

Grifols Stock Performance

Shares of GRFS stock traded down $0.02 during trading hours on Tuesday, hitting $7.13. The stock had a trading volume of 216,988 shares, compared to its average volume of 1,204,796. The firm has a market capitalization of $4.90 billion, a PE ratio of 6.10 and a beta of 0.41. Grifols, S.A. has a twelve month low of $5.79 and a twelve month high of $9.96. The stock's 50 day moving average is $7.47 and its 200 day moving average is $7.74. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.